Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Ther Adv Med Oncol
; 13: 1758835920980558, 2021.
Article
in En
| MEDLINE
| ID: mdl-33613692
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Ther Adv Med Oncol
Year:
2021
Type:
Article